
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5729880/publications.pdf Version: 2024-02-01



FEDERICO PEA

#	Article	IF	CITATIONS
1	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatology, The, 2020, 2, e474-e484.	3.9	772
2	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. Intensive Care Medicine, 2020, 46, 1127-1153.	8.2	504
3	The effect of pathophysiology on pharmacokinetics in the critically ill patient — Concepts appraised by the example of antimicrobial agents. Advanced Drug Delivery Reviews, 2014, 77, 3-11.	13.7	351
4	Antimicrobial Therapy in Critically III Patients. Clinical Pharmacokinetics, 2005, 44, 1009-1034.	3.5	316
5	The Clinical Relevance of Plasma Protein Binding Changes. Clinical Pharmacokinetics, 2013, 52, 1-8.	3.5	225
6	Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 2034-2042.	3.0	208
7	Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomaterials, 1993, 14, 1154-1160.	11.4	198
8	An international, multicentre survey of Â-lactam antibiotic therapeutic drug monitoring practice in intensive care units. Journal of Antimicrobial Chemotherapy, 2014, 69, 1416-1423.	3.0	185
9	Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2012, 67, 17-24.	3.0	177
10	Pharmacokinetic Considerations for Antimicrobial Therapy in Patients Receiving Renal Replacement Therapy. Clinical Pharmacokinetics, 2007, 46, 997-1038.	3.5	174
11	Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis. Antimicrobial Agents and Chemotherapy, 2010, 54, 4605-4610.	3.2	172
12	Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock – does the dose matter?. Critical Care, 2009, 13, 214.	5.8	157
13	The Antimicrobial Therapy Puzzle: Could Pharmacokinetic-Pharmacodynamic Relationships Be Helpful in Addressing the Issue of Appropriate Pneumonia Treatment in Critically III Patients?. Clinical Infectious Diseases, 2006, 42, 1764-1771.	5.8	133
14	Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit. Clinical Pharmacokinetics, 2001, 40, 833-868.	3.5	123
15	Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. Journal of Antimicrobial Chemotherapy, 2003, 51, 971-975.	3.0	120
16	Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2009, 53, 1863-1867.	3.2	113
17	Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. International Journal of Infectious Diseases, 2010, 14, S79-S92.	3.3	102
18	High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. Journal of Antimicrobial Chemotherapy, 2000, 45, 329-335.	3.0	101

#	Article	IF	CITATIONS
19	Ceftolozane/tazobactam: place in therapy. Expert Review of Anti-Infective Therapy, 2018, 16, 307-320.	4.4	100
20	Methicillin-resistant Staphylococcus aureus infections: A review of the currently available treatment options. Journal of Global Antimicrobial Resistance, 2016, 7, 178-186.	2.2	87
21	Dosing Nomograms for Attaining Optimum Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach. Antimicrobial Agents and Chemotherapy, 2012, 56. 6343-6348.	3.2	76
22	Teicoplanin in Patients with Acute Leukaemia and Febrile Neutropenia. Clinical Pharmacokinetics, 2004, 43, 405-415.	3.5	74
23	Hyperlactacidemia Potentially Due to Linezolid Overexposure in a Liver Transplant Recipient. Clinical Infectious Diseases, 2006, 42, 434-435.	5.8	73
24	A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: Application to critically ill pediatric patients. Journal of Pharmaceutical and Biomedical Analysis, 2020, 186, 113273.	2.8	67
25	Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?. International Journal of Antimicrobial Agents, 2017, 49, 255-258.	2.5	65
26	A 10â€Year Experience of Therapeutic Drug Monitoring ( <scp>TDM</scp> ) of Linezolid in a Hospitalâ€wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting <scp>TDM</scp> in the Majority of Patients?. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 303-308.	2.5	64
27	Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	63
28	WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. World Journal of Emergency Surgery, 2011, 6, 2.	5.0	57
29	Challenges in the management of chronic wound infections. Journal of Global Antimicrobial Resistance, 2021, 26, 140-147.	2.2	56
30	Pharmacology of Drugs for Hyperuricemia. , 2004, 147, 35-46.		54
31	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clinical Microbiology and Infection, 2021, 27, 671-686.	6.0	54
32	Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin in Patients with Early-Onset Ventilator-Associated Pneumonia. Clinical Pharmacokinetics, 2003, 42, 589-598.	3.5	53
33	TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. International Journal of Antimicrobial Agents, 2002, 20, 326-332.	2.5	52
34	TDM-Guided Therapy with Daptomycin and Meropenem in a Morbidly Obese, Critically Ill Patient. Annals of Pharmacotherapy, 2011, 45, 1022-1022.	1.9	52
35	Levofloxacin Disposition in Cerebrospinal Fluid in Patients with External Ventriculostomy. Antimicrobial Agents and Chemotherapy, 2003, 47, 3104-3108.	3.2	51
36	Procalcitonin-guided antibiotic therapy: an expert consensus. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1223-1229.	2.3	51

#	Article	IF	CITATIONS
37	Ceftazidime in Acute Myeloid Leukemia Patients with Febrile Neutropenia: Helpfulness of Continuous Intravenous Infusion in Maximizing Pharmacodynamic Exposure. Antimicrobial Agents and Chemotherapy, 2005, 49, 3550-3553.	3.2	49
38	Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. British Journal of Haematology, 1999, 106, 92-99.	2.5	48
39	Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically III Patients Affected by Documented Gram-Negative Infections. Antibiotics, 2021, 10, 1311.	3.7	47
40	Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. Journal of Antimicrobial Chemotherapy, 2006, 58, 380-386.	3.0	44
41	Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	44
42	A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol. Journal of Global Antimicrobial Resistance, 2021, 27, 294-298.	2.2	44
43	Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. Clinical Pharmacokinetics, 2016, 55, 1507-1520.	3.5	42
44	Ceftobiprole: drug evaluation and place in therapy. Expert Review of Anti-Infective Therapy, 2019, 17, 689-698.	4.4	42
45	Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. Critical Care, 2022, 26, .	5.8	41
46	Pharmacodynamics of teicoplanin against MRSA. Journal of Antimicrobial Chemotherapy, 2017, 72, 3382-3389.	3.0	40
47	Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Current Clinical Pharmacology, 2013, 8, 5-12.	0.6	39
48	Cerebrospinal Fluid Penetration of Levofloxacin in Patients with Spontaneous Acute Bacterial Meningitis. Clinical Infectious Diseases, 2001, 33, e109-e111.	5.8	38
49	Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant <i>Pseudomonas aeruginosa</i> (DTR-P) infections. JAC-Antimicrobial Resistance, 2021, 3, dlab188.	2.1	38
50	Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin. International Journal of Antimicrobial Agents, 2009, 33, 379-382.	2.5	36
51	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). International Journal	2.5	36
52	Or Antimicrobial Agents, 2022, 60, 1065 CC Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. Journal of Antimicrobial Chemotherapy, 2019, 74, 3588-3595.	3.0	35
53	Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: A report of 2 cases. American Journal of Kidney Diseases, 2004, 44, 1097-1102.	1.9	34
54	Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450( <scp>CYP</scp> ) Inhibitors and/or with <scp>CYP</scp> Inhibitors plus <scp>CYP</scp> Inducers. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 474-479.	2.5	34

#	Article	IF	CITATIONS
55	Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. Drug Design, Development and Therapy, 2021, Volume 15, 3349-3378.	4.3	34
56	Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy, 2003, 51, 101-106.	3.0	33
57	Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMIÂ≥40Âkg/m2) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring. Clinical Pharmacokinetics, 2014, 53, 753-762.	3.5	33
58	Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. Journal of Antimicrobial Chemotherapy, 2015, 70, 198-206.	3.0	33
59	Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections. Clinical Pharmacokinetics. 2015. 54. 933-941.	3.5	31
60	Overview of antifungal dosing in invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2018, 73, i33-i43.	3.0	31
61	Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. Expert Review of Clinical Pharmacology, 2021, 14, 583-599.	3.1	31
62	Clinical??Relevance??of??Pharmacokinetics and??Pharmacodynamics??in Cardiac??Critical??Care??Patients. Clinical Pharmacokinetics, 2008, 47, 449-462.	3.5	30
63	Pneumonia in frail older patients: an up to date. Internal and Emergency Medicine, 2012, 7, 415-424.	2.0	30
64	Population Pharmacokinetics of Teicoplanin in Children. Antimicrobial Agents and Chemotherapy, 2014, 58, 6920-6927.	3.2	29
65	LEVODOPA AND 3-O-METHYLDOPA IN CEREBROSPINAL FLUID AFTER LEVODOPA-CARBIDOPA ASSOCIATION. Pharmacological Research, 1997, 35, 313-315.	7.1	28
66	Should the Currently Recommended Twice-DailyÂDosingÂStillÂbeÂConsidered theÂMostÂAppropriateÂRegimenÂfor TreatingÂMRSAÂVentilator-Associated PneumoniaÂwithÂVancomycin?. Clinical Pharmacokinetics, 2008, 47, 147-152.	3.5	28
67	Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	28
68	Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infectious Diseases, 2021, 34, 737-747.	3.1	28
69	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2021, 10, 1837-1885.	4.0	28
70	Pharmacokinetic Interaction Between Everolimus and Antifungal Triazoles in a Liver Transplant Patient. Annals of Pharmacotherapy, 2008, 42, 1711-1716.	1.9	27
71	Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications. Clinical Pharmacokinetics, 2018, 57, 177-189.	3.5	27
72	Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics. Clinical Pharmacokinetics, 2021, 60, 1271-1289.	3.5	27

#	Article	lF	CITATIONS
73	Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. Cancer Chemotherapy and Pharmacology, 2000, 46, 279-286.	2.3	26
74	Stability of Generic Meropenem Solutions for Administration by Continuous Infusion at Normal and Elevated Temperatures. Therapeutic Drug Monitoring, 2014, 36, 674-676.	2.0	26
75	Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. Clinical Pharmacokinetics, 2018, 57, 989-1000.	3.5	26
76	Pharmacokinetics and drug metabolism of antibiotics in the elderly. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1087-1100.	3.3	26
77	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. Journal of Antimicrobial Chemotherapy, 2017, 72, 2342-2350.	3.0	26
78	Multidrug resistance modulation in vivo: The effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. European Journal of Clinical Pharmacology, 1999, 55, 361-368.	1.9	25
79	Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. Clinical Pharmacokinetics, 2020, 59, 1251-1260.	3.5	25
80	The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Expert Review of Anti-Infective Therapy, 2020, 18, 415-422.	4.4	25
81	Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?. Infectious Diseases and Therapy, 2020, 9, 137-149.	4.0	25
82	Therapeutic Drug Monitoring–Guided High Teicoplanin Dosage Regimen Required to Treat a Hypoalbuminemic Renal Transplant Patient Undergoing Continuous Venovenous Hemofiltration. Therapeutic Drug Monitoring, 2001, 23, 587-588.	2.0	25
83	Italian Guidelines for Diagnosis, Prevention, and Treatment of Invasive Fungal Infections in Solid Organ Transplant Recipients. Transplantation Proceedings, 2011, 43, 2463-2471.	0.6	24
84	Successful Long-Term Treatment of Cerebral Nocardiosis with Unexpectedly Low Doses of Linezolid in an Immunocompromised Patient Receiving Complex Polytherapy. Antimicrobial Agents and Chemotherapy, 2012, 56, 3438-3440.	3.2	24
85	Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderl. Pharmacoepidemiology and Drug Safety, 2016, 25, 1070-1078.	1.9	24
86	Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	24
87	Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3029-3037.	3.0	24
88	Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: Dose Intensification Coupled with Avoidance of Proton Pump Inhibitors Is Beneficial in Shortening Time to Effective Concentrations. Antimicrobial Agents and Chemotherapy, 2013, 57, 6081-6084.	3.2	23
89	Plasma Pharmacokinetics of Antimicrobial Agents in Critically III Patients. Current Clinical Pharmacology, 2013, 8, 5-12.	0.6	23
90	Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. Journal of Antimicrobial Chemotherapy, 2014, 69, 2585-2586.	3.0	23

#	Article	IF	CITATIONS
91	Identification and management of invasive mycoses in internal medicine: a road-map for physicians. Internal and Emergency Medicine, 2014, 9, 501-511.	2.0	23
92	Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections. Current Opinion in Infectious Diseases, 2016, 29, 153-159.	3.1	23
93	Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?. Clinical Microbiology and Infection, 2020, 26, 1024-1033.	6.0	23
94	Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis. Diagnostic Microbiology and Infectious Disease, 2007, 58, 137-139.	1.8	22
95	Occurrence and Extent of Bruising According to Duration of Administration of Subcutaneous Low-Molecular-Weight Heparin. Journal of Cardiovascular Nursing, 2013, 28, 473-482.	1.1	22
96	Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections. Expert Review of Anti-Infective Therapy, 2019, 17, 819-827.	4.4	22
97	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Infection and Drug Resistance, 2020, Volume 13, 4697-4711.	2.7	21
98	Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. Leukemia, 1998, 12, 1236-1240.	7.2	20
99	Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500mg oral dose. Pharmacological Research, 2007, 55, 38-41.	7.1	20
100	Coâ€administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayedâ€released tablets in adult patients with haematological malignancies. British Journal of Clinical Pharmacology, 2018, 84, 2544-2550.	2.4	20
101	Oral Gabapentin Disposition in Patients with Epilepsy After a High-Protein Meal. Epilepsia, 1997, 38, 1140-1142.	5.1	19
102	Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1193-1200.	3.3	19
103	Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant. Infection, 2018, 46, 263-265.	4.7	19
104	Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. Journal of Infection and Chemotherapy, 2020, 26, 900-907.	1.7	19
105	Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept. International Journal of Antimicrobial Agents, 2021, 58, 106445.	2.5	19
106	Long-Term Outcomes of Orthotopic Liver Transplantation in Human Immunodeficiency Virus–Infected Patients and Comparison With Human Immunodeficiency Virus–Negative Cases. Transplantation Proceedings, 2011, 43, 1119-1122.	0.6	18
107	Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection, 2014, 42, 207-210.	4.7	18
108	A 1Âyear retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?. British Journal of Clinical Pharmacology, 2016, 81, 341-348.	2.4	18

#	Article	IF	CITATIONS
109	Sonidegib for the Treatment of Advanced Basal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 582866.	2.8	18
110	Effects of different sampling strategies on predictions of blood cyclosporine concentrations in haematological patients with multidrug resistance by bayesian and non-linear least squares methods. Pharmacological Research, 1995, 32, 355-362.	7.1	17
111	The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin. International Journal of Antimicrobial Agents, 2006, 27, 344-350.	2.5	17
112	Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections. Expert Review of Anti-Infective Therapy, 2007, 5, 255-270.	4.4	17
113	Penetration of Antibacterials into Bone. Clinical Pharmacokinetics, 2009, 48, 125-127.	3.5	17
114	Does Critical Illness Change Levofloxacin Pharmacokinetics?. Antimicrobial Agents and Chemotherapy, 2016, 60, 1459-1463.	3.2	17
115	Protocol implementation in hospital infection control practice: an Italian experience of preoperative antibiotic prophylaxis. Journal of Hospital Infection, 2001, 47, 288-293.	2.9	16
116	Pharmacokinetics and Pharmacodynamics of Continuous-Infusion Meropenem in Pediatric Hematopoietic Stem Cell Transplant Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 5535-5541.	3.2	16
117	Blood Concentrations and Clinical Effect of Cyclosporin in Psoriasis. Therapeutic Drug Monitoring, 1996, 18, 544-548.	2.0	16
118	Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient. International Journal of Infectious Diseases, 2021, 113, 213-217.	3.3	15
119	An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically III Adult Patients. Antibiotics, 2022, 11, 33.	3.7	15
120	Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia. Journal of Chemotherapy, 2003, 15, 563-567.	1.5	14
121	Antimicrobial treatment of bacterial infections in frail elderly patients: the difficult balance between efficacy, safety and tolerability. Current Opinion in Pharmacology, 2015, 24, 18-22.	3.5	14
122	An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically III Adult Patients. Infection and Drug Resistance, 2021, Volume 14, 2461-2498.	2.7	14
123	What is the Role of Fluoroquinolones in Intensive Care?. Journal of Chemotherapy, 2003, 15, 5-10.	1.5	13
124	Linezolid Underexposure in a Hypothyroid Patient on Levothyroxine Replacement Therapy. Therapeutic Drug Monitoring, 2014, 36, 687-689.	2.0	13
125	Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients. Intensive Care Medicine, 2015, 41, 366-368.	8.2	13
126	Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?. Journal of Antimicrobial Chemotherapy, 2016, 71, 1323-1329.	3.0	13

#	Article	IF	CITATIONS
127	Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. Clinical Pharmacokinetics, 2018, 57, 1399-1405.	3.5	13
128	Acute wound infections management: the †Don'ts' from a multidisciplinary expert panel. Expert Review of Anti-Infective Therapy, 2020, 18, 231-240.	4.4	13
129	Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases. Microorganisms, 2022, 10, 154.	3.6	13
130	CYCLOSPORIN NEPHROTOXICITY IN RELATION TO ITS METABOLISM IN PSORIASIS. Pharmacological Research, 1996, 33, 349-352.	7.1	12
131	Isoniazid and its Hydrazine Metabolite in Patients with Tuberculosis. Clinical Drug Investigation, 1999, 17, 145-154.	2.2	12
132	Pharmacokinetic and Pharmacodynamic Aspects of Oral Moxifloxacin 400 mg/day in Elderly Patients with Acute Exacerbation of Chronic Bronchitis. Clinical Pharmacokinetics, 2006, 45, 287-295.	3.5	12
133	Gentamicin once-daily in enterococcal endocarditis. International Journal of Cardiology, 2013, 168, 5033-5034.	1.7	12
134	Limited sampling strategies for determining the area under the plasma concentration–time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis. International Journal of Antimicrobial Agents, 2017, 50, 23-28.	2.5	12
135	Treatment of <i>Candida</i> infections with fluconazole in adult liver transplant recipients: Is TDMâ€guided dosing adaptation helpful?. Transplant Infectious Disease, 2019, 21, e13113.	1.7	12
136	Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2021, 58, 106408.	2.5	12
137	Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically III Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. Frontiers in Pharmacology, 2021, 12, 781892.	3.5	12
138	Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?. Pharmaceutics, 2021, 13, 2099.	4.5	12
139	Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia. Clinical Pharmacokinetics, 2003, 42, 851-862.	3.5	11
140	Monitoring Polypharmacy in Healthcare Systems through a Multi-Setting Survey: Should We Put More Attention on Long Term Care Facilities?. Journal of Public Health Research, 2016, 5, jphr.2016.745.	1.2	11
141	Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2019, 74, 1648-1655.	3.0	11
142	The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Review of Anti-Infective Therapy, 2021, 19, 1125-1134.	4.4	11
143	Optimisation of Vancomycin Regimen in Neutropenic Haematological Patients with Normal Renal Function. Clinical Drug Investigation, 2000, 19, 213-218.	2.2	10
144	Levofloxacin Disposition over Time in Aqueous Humor of Patients Undergoing Cataract Surgery. Antimicrobial Agents and Chemotherapy, 2005, 49, 2554-2557.	3.2	10

#	Article	IF	CITATIONS
145	Linezolid underexposure in a patient co-treated with venlafaxine. European Journal of Clinical Pharmacology, 2015, 71, 1285-1286.	1.9	10
146	Interlaboratory Analysis of Isavuconazole Plasma Concentration Assays Among European Laboratories. Therapeutic Drug Monitoring, 2019, 41, 657-664.	2.0	10
147	Pharmacokinetic Profile of Two Different Administration Schemes of Teicoplanin. Clinical Drug Investigation, 1999, 18, 47-55.	2.2	9
148	Quale Ruolo per i Fluorochinoloni in Terapia Intensiva?. Journal of Chemotherapy, 2003, 15, 5-10.	1.5	9
149	Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients. Journal of Antimicrobial Chemotherapy, 2008, 63, 167-169.	3.0	9
150	Current pharmacological concepts for wise use of echinocandins in the treatment ofCandidainfections in septic critically ill patients. Expert Review of Anti-Infective Therapy, 2013, 11, 989-997.	4.4	9
151	Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis. Annals of Pharmacotherapy, 2015, 49, 978-985.	1.9	9
152	Effect of the Number of Samples on Bayesian and Non-linear Least-squares Individualization: A Study of Cyclosporin Treatment of Haematological Patients with Multidrug Resistance. Journal of Pharmacy and Pharmacology, 2011, 50, 343-349.	2.4	8
153	Successful and safe longâ€term treatment of cerebral aspergillosis with highâ€dose voriconazole guided by therapeutic drug monitoring. British Journal of Clinical Pharmacology, 2019, 85, 266-269.	2.4	8
154	Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies. CNS Drugs, 2021, 35, 345-384.	5.9	8
155	Ciprofloxacin Disposition in Elderly Patients with LRTI Being Treated with Sequential Therapy (200 mg) Tj ETQq1 the Role of Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2000, 22, 386-391.	1 0.78431 2.0	.4 rgBT /Ov <mark>er</mark> 8
156	Treatment options for community-acquired pneumonia in the elderly people. Expert Review of Anti-Infective Therapy, 2015, 13, 473-85.	4.4	8
157	Preface. Journal of Chemotherapy, 2003, 15, 3-3.	1.5	7
158	What Should Be the First-Choice Strategy To Maximize Posaconazole Exposure in Daily Clinical Practice?. Antimicrobial Agents and Chemotherapy, 2009, 53, 3608-3610.	3.2	7
159	HIV-Infected Patients and Liver Transplantation: Who, When and Why. Current HIV Research, 2011, 9, 120-127.	0.5	7
160	Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. International Journal of Antimicrobial Agents, 2014, 44, 570-571.	2.5	7
161	Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient. European Journal of Clinical Pharmacology, 2018, 74, 1671-1672.	1.9	7
162	Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically III Morbidly Obese Patient. Grand Round/A Case Study. Therapeutic Drug Monitoring, 2020, 42, 349-352.	2.0	7

#	Article	IF	CITATIONS
163	Population Pharmacokinetics and Monte Carlo Simulation for Dosage Optimization of Fosfomycin in the Treatment of Osteoarticular Infections in Patients without Renal Dysfunction. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	7
164	An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients. Expert Review of Anti-Infective Therapy, 2022, 20, 331-352.	4.4	7
165	Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. Antiviral Therapy, 2008, 13, 739-742.	1.0	7
166	Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients. Pharmacological Research, 2001, 43, 547-551.	7.1	6
167	Levofloxacin PK/PD: from Sequential Therapy Model to High Dosage for Critical Patients. Journal of Chemotherapy, 2004, 16, 8-10.	1.5	6
168	Is the Minimum Inhibitory Concentration of Vancomycin an Infallible Predictor of the Clinical Outcome of <i>Staphylococcus aureus</i> Bacteremia Treated with Vancomycin?. Clinical Infectious Diseases, 2009, 49, 642-643.	5.8	6
169	Vancomycin Way of Administration: Where is the Evidence?. Clinical Infectious Diseases, 2011, 53, 308-310.	5.8	6
170	Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia. Transplant Infectious Disease, 2015, 17, 926-928.	1.7	6
171	ls empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience. Intensive Care Medicine, 2015, 41, 2026-2028.	8.2	6
172	Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review. Journal of NeuroVirology, 2017, 23, 908-912.	2.1	6
173	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp European Journal of Clinical Pharmacology, 2018, 74, 1449-1459.	1.9	6
174	Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosa. Pharmaceutics, 2020, 12, 785.	4.5	6
175	A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings. Frontiers in Pharmacology, 2021, 12, 755075.	3.5	6
176	CYCLOSPORINE A PHARMACOKINETICS IN RHEUMATOID ARTHRITIS PATIENTS AFTER 6 MONTHS OF METHOTREXATE THERAPY. Pharmacological Research, 1999, 40, 483-486.	7.1	5
177	Could De-escalation of Antibiotic Therapy be Feasible Even for Documented Methicillin-Resistant Staphylococcus aureus Ventilator-Associated Pneumonia?. Journal of Trauma, 2009, 67, 893-894.	2.3	5
178	Educational and Organizational Interventions to Improve the Usefulness of Clinical Pharmacological Advice for Personalized Drug Dosing Based on Therapeutic Drug Monitoring. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 432-437.	2.5	5
179	A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant Staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy. Diagnostic Microbiology and Infectious Disease, 2015, 81, 53-56.	1.8	5
180	Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. European Journal of Clinical Pharmacology, 2018, 74, 1091-1092.	1.9	5

#	Article	IF	CITATIONS
181	Actoxumab + bezlotoxumab combination: what promise for <i>Clostridium difficile</i> treatment?. Expert Opinion on Biological Therapy, 2018, 18, 469-476.	3.1	5
182	Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. Expert Review of Anti-Infective Therapy, 2021, 19, 1373-1383.	4.4	5
183	Systemic Vancomycin Overexposure in a Patient With Spinal Cord Injury Who Had Staphylococcal Sepsis and Clostridium difficile Colitis. Therapeutic Drug Monitoring, 2000, 22, 233-234.	2.0	5
184	Is antimicrobial underexposure due to glomerular hyperfiltration a possible cause of increased mortality rate from bacterial infections in critically ill patients?. Anaesthesia and Intensive Care, 2009, 37, 323-4.	0.7	5
185	Penetration of antibacterials into bone: what do we really need to know for optimal prophylaxis and treatment of bone and joint infections?. Clinical Pharmacokinetics, 2009, 48, 125-7.	3.5	5
186	Enhancement ofIn- VitroActivity of Ofloxacin and Gentamicin by Rat Serum. Journal of Chemotherapy, 1990, 2, 368-370.	1.5	4
187	Hallucinations During Voriconazole Therapy: Who Is at Higher Risk and Could Benefit From Therapeutic Drug Monitoring?. Therapeutic Drug Monitoring, 2009, 31, 135-136.	2.0	4
188	Antiretroviral blood levels in <scp>HIV</scp> / <scp>HCV</scp> oinfected patients with cirrhosis after liver transplant: a report of three cases. Transplant Infectious Disease, 2015, 17, 147-153.	1.7	4
189	Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?. Journal of Global Antimicrobial Resistance, 2018, 14, 238-241.	2.2	4
190	From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis. Mycoses, 2020, 63, 854-858.	4.0	4
191	The role of procalcitonin in reducing antibiotics across the surgical pathway. World Journal of Emergency Surgery, 2021, 16, 15.	5.0	4
192	Effect of fluctuations of blood cyclosporine concentrations on renal function. Transplantation Proceedings, 1994, 26, 2574-5.	0.6	4
193	Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies. Therapeutic Drug Monitoring, 2022, 44, 641-650.	2.0	4
194	Prediction of cyclosporine blood concentrations in hematological patients with multidrug resistance. Pharmacological Research, 1995, 31, 44.	7.1	3
195	Pharmacokinetic–pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery. International Journal of Antimicrobial Agents, 2006, 27, 15-19.	2.5	3
196	Biliary pharmacodynamic exposure to linezolid in two liver transplant patients. Journal of Antimicrobial Chemotherapy, 2014, 69, 567-568.	3.0	3
197	Urological Infections Due to Multidrug-Resistant Bacteria: What We Need to Know?. Urologia, 2016, 83, 21-26.	0.7	3
198	A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care. International Journal of Tuberculosis and Lung Disease, 2019, 23, 1042-1042.	1.2	3

#	Article	IF	CITATIONS
199	Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply. Lancet Rheumatology, The, 2020, 2, e739-e740.	3.9	3
200	Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections?. Clinical Pharmacokinetics, 2021, 60, 403-407.	3.5	3
201	Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and metaâ€analysis. Mycoses, 2021, 64, 1317-1327.	4.0	3
202	Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring. Infectious Disease Reports, 2022, 14, 88-92.	3.1	3
203	Serum concentrations of sodium 2-mercaptoethanesulfonate (MESNA) and its metabolite, disulfide form (DIMESNA), in volunteers after oral dosing: A comparison between mesna and argimesna Pharmacological Research, 1992, 25, 85-86.	7.1	2
204	Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients. Transplantation Proceedings, 2001, 33, 3151-3153.	0.6	2
205	MEGX disposition in critically-ill trauma patients: subsequent assessments during the first week following trauma. Fundamental and Clinical Pharmacology, 2002, 16, 519-525.	1.9	2
206	Treatment of Post-Traumatic HandStaphylococcus aureusOsteomyelitis with Oral Linezolid. Journal of Chemotherapy, 2006, 18, 425-429.	1.5	2
207	The <i>Charta</i> of Milan: Basic Criteria for the Appropriate and Accurate Use of Antibiotics: Recommendations of the Italian Society of Chemotherapy. Journal of Chemotherapy, 2009, 21, 475-481.	1.5	2
208	Continuous Infusion May Improve the Efficacy of Vancomycin in Treatment of Experimental Endocarditis Due to Heterogeneous Vancomycin-Intermediate Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2011, 55, 4496-4497.	3.2	2
209	Comparison of clinical characteristics of tuberculosis between two age groups at an Italian Tertiary Hospital. Infection, 2015, 43, 361-366.	4.7	2
210	Editorial overview: Anti-infectives: Current challenges and unmet needs in antimicrobial therapy. Current Opinion in Pharmacology, 2015, 24, iv-vi.	3.5	2
211	β-Blockers and Diltiazem Combination—Bear in Mind the Risk of Heart Block. JAMA Internal Medicine, 2017, 177, 1543.	5.1	2
212	Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report. Drugs and Therapy Perspectives, 2018, 34, 402-403.	0.6	2
213	Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients. Current Clinical Pharmacology, 2013, 8, 5-12.	0.6	2
214	Immunologic and Pharmacologic Aspects in an Elderly Recipient of Liver Transplant With Pulmonary Aspergillosis and Multiple Comorbidities. Experimental and Clinical Transplantation, 2016, 14, 567-570.	0.5	2
215	Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency. Clinical Pharmacokinetics, 2022, 61, 505-513.	3.5	2
216	Comparison of the Antibacterial Activity and Synergistic Activity Towards Antibiotics of Different Mammalian Sera. Journal of Chemotherapy, 1993, 5, 10-13.	1.5	1

#	Article	IF	CITATIONS
217	What does it mean: Appropriate therapy for methicillin-resistant Staphylococcus aureus?. Critical Care Medicine, 2007, 35, 991.	0.9	1
218	A multi-society position paper on the prevention and management of nosocomial and severe infections: the Italian Society for Infectious Diseases, the Italian Multidisciplinary Society of Hospital Infections, the Italian Society of Chemotherapy, the Italian Society of Respiratory Medicine, the Italian Society of Clinical Microbiology, the Italian Society of Microbiology, and GISIG (Italian Study Group) Tj ETQq0 0 (	3.3 ) rgBT /Ov	1 verlock 10 Tf 5
219	Daptomycin in solid organ transplantation: consideration of dosage adjustments in renal impairment. Transplant Infectious Disease, 2014, 16, 868-869.	1.7	1
220	Physiological Manifestations of Critical Illness. , 2018, , 31-46.		1
221	Principles of Pharmacodynamics and Pharmacokinetics of Drugs Used in Extracorporeal Therapies. , 2019, , 892-896.e1.		1
222	Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?― Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0190821.	3.2	1
223	A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2022, 11, 635-638.	4.0	1
224	Assessment of the impact of clinical recommendations on antibiotic use for CAP and HCAP: results from an implementation program in an Academic Hospital. Annali Di Igiene: Medicina Preventiva E Di Comunita, 2020, 32, 344-356.	0.7	1
225	Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. Antiviral Therapy, 2008, 13, 739-42.	1.0	1
226	A Comparative Analysis of the Urinary Excretion Profiles of Mesna and Argimesna Following Oral Administration to Healthy Volunteers. Drug Investigation, 1992, 4, 391-394.	0.6	0
227	Study on the Bactericidal Activity and Synergistic Effect of Neutropenic Rat Serum with Gentamicin. Journal of Chemotherapy, 1994, 6, 117-120.	1.5	Ο
228	Is the Use of Vancomycin Doses of At Least 1 g Every 8 Hours the Only Way to Achieve Optimal Trough Levels in Critically III Trauma Patients With Pneumonia and Normal Renal Function?. Journal of Trauma, 2010, 68, 748-749.	2.3	0
229	Antibiotic therapy in hematological neutropenic patients: what is the news?. Leukemia Supplements, 2012, 1, S20-S21.	0.1	Ο
230	Polypharmacy in an Italian Regional Health system: a survey on drugs use in different healthcare settings. European Journal of Public Health, 2014, 24, .	0.3	0
231	A regional approach to Antimicrobial Stewardship: the Friuli Venezia Giulia program. European Journal of Public Health, 2015, 25, .	0.3	Ο
232	Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections. Expert Review of Anti-Infective Therapy, 2015, 13, 927-937.	4.4	0
233	Reply. Annals of Pharmacotherapy, 2016, 50, 153-153.	1.9	Ο
234	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. Journal of Chemotherapy, 2018, 30, 157-171.	1.5	0

#	Article	IF	CITATIONS
235	Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis. Hematological Oncology, 2021, 39, 20-26.	1.7	0
236	Authors' Reply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6― Clinical Pharmacokinetics, 2021, 60, 833-834.	3.5	0
237	Principles of Pharmacodynamics and Pharmacokinetics of Drugs Used in Extracorporeal Therapies. , 2009, , 1190-1194.		0
238	Drugs and Blood Cells. , 2015, , 111-147.		0
239	Nosocomial Pneumonia: Strategies for Management: General Pharmacological Considerations and Dose Adjustment in Antibiotic Therapy for HAP. , 0, , 173-189.		0